Cite
HARVARD Citation
Dutriaux, C. et al. (2022). An open label, non-randomised, phase IIIb study of trametinib in combination with dabrafenib in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: A subgroup analysis of patients with brain metastases. European journal of cancer. pp. 254-262. [Online].